Additional Holter and Telemetry Equipment Introduced

Posted:
7
January 2005

As demand for our QTc studies grows, we recently introduced new Holter and Telemetry equipment to enhance this crucial new service.When evaluating new medicines during early phase clinical trials, it is crucial that the impact on the cardiovascular system is monitored continuously. Furthermore, the demand for QTc studies has increased due to undesired side-effects of medicines that prolong cardiac repolarization such as pimozide, thioridazine and cisapride.Ambulatory Holter monitoring as well as continuous Telemetry ECG monitoring are the two new services that we provide at Richmond complementing our QTc Study set up.Our Holter monitors allow the recording of ambulatory ECGs over a continuous period up to 48 hours, whilst not disturbing the normal daily routine of our volunteers. In addition, using our Telemetry system, volunteers are monitored 24 hours a day, 7 days a week whilst in the research unit.Having a dedicated team of Research Physicians who, in conjunction with Cardiologists from the St George's Hospital Medical School, constantly monitor the volunteers enables immediate access to volunteer information and helping to speed analysis and any necessary action.At Richmond Pharmacology we are dedicated to the well being and safety of volunteers. We continue to make every effort acquiring the latest technology to provide our clients with excellent clinical trial services.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more